Raphaël Janela-Lapert

Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study

BACKGROUND: Mogamulizumab, an anti-CCR4 monoclonal antibody used in advanced mycosis fungoides (MF) and Sezary syndrome (SS), also depletes regulatory T cells, potentially leading to immune-related adverse events (irAEs). Unlike mogamulizumab-associated rash (MAR), other irAEs re...